Zeo ScientifiXZEOX -2.34%52 Return-on-Tangible-Equity is -352.58% as of Apr. 2026. GuruFocus rates ZEOX with a GF Score™ of 52/100 and a GF Value™ of $2.66 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,195 Biotechnology companies, Zeo ScientifiX ranks worse than 83681.92% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Zeo ScientifiX's annualized net income for the quarter that ended in Apr. 2026 was $-0.58 Mil. Zeo ScientifiX's average shareholder tangible equity for the quarter that ended in Apr. 2026 was $0.16 Mil. Therefore, Zeo ScientifiX's annualized Return-on-Tangible-Equity for the quarter that ended in Apr. 2026 was -352.58%.
The historical rank and industry rank for Zeo ScientifiX's Return-on-Tangible-Equity or its related term are showing as below:
ZEOX's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.21 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Zeo ScientifiX Return-on-Tangible-Equity Related Terms
Zeo ScientifiX Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Zeo ScientifiX's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZEOX vs JUNS, HOOK, LEXX: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Zeo ScientifiX's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeo ScientifiX Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Apr. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -352.58% mean?
Zeo ScientifiX (ZEOX) has a Return-on-Tangible-Equity of -352.58% as of Apr. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zeo ScientifiX and its competitors. According to the industry distribution chart, Zeo ScientifiX ranks #999999 out of 1195 companies in the Biotechnology industry.
Is Zeo ScientifiX's Return-on-Tangible-Equity too high?
Zeo ScientifiX's current Return-on-Tangible-Equity is -352.58%. Based on the distribution chart, Zeo ScientifiX ranks #999999 out of 1195 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zeo ScientifiX has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zeo ScientifiX's Return-on-Tangible-Equity compare to JUNS and HOOK?
According to the Biotechnology industry distribution chart, Zeo ScientifiX ranks #999999 out of 1195 companies for Return-on-Tangible-Equity. This places Zeo ScientifiX in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zeo ScientifiX and its competitors. Zeo ScientifiX's current Return-on-Tangible-Equity is -352.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeo ScientifiX stock overvalued right now?
Based on GuruFocus' analysis, Zeo ScientifiX (ZEOX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.66, compared to a current price of $1.77 — trading 33.5% below its estimated fair value. The current Return-on-Tangible-Equity is -352.58%. Zeo ScientifiX's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Zeo ScientifiX (ZEOX), the current Return-on-Tangible-Equity is -352.58% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zeo ScientifiX (ZEOX) Overvalued in 2026?
Based on GuruFocus' analysis, Zeo ScientifiX stock appears to be undervalued.
The current stock price of $1.77 is trading 33.5% below its estimated GF Value™ of $2.66.
GuruFocus considers Zeo ScientifiX to be Possible Value Trap.
Key valuation signals for ZEOX:
Return-on-Tangible-Equity: -352.58%
GF Value™: $2.66 vs. price of $1.77 (33.5% below fair value)
No single metric tells the full story. See the ZEOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
52GF Score
Get the complete analysis for ZEOX
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZEOX has been successfully added to your 
